Manufactured Growth: Uncovering Revenue Manipulation in Pharma
-
October 12, 2026
-
Revenue manipulation is rarely obvious. A sales manager persuades a wholesaler to take six months of inventory instead of two at quarter-end. A customer receives an informal assurance that unsold product can be returned. A distributor receives terms that are economically similar to consignment inventory.
Individually, these actions go unnoticed. Collectively, they can distort publicly reported financial results and hide business performance issues. And when employees feel pressure to generate or sustain growth, the issue is rarely isolated to one individual or transaction. Revenue manipulation often stems from pressure to meet earnings expectations.
The consequences of manufactured growth in reported sales can be severe for public companies, including regulatory scrutiny, missed filing deadlines, reporting deficiencies, financial restatements and even exchange listing concerns.
Why are pharmaceutical companies vulnerable to revenue manipulation, and how should they respond when concerns arise?
How Revenue Manipulation Actually Happens
Enforcement cases and internal investigations consistently show that pressure to meet performance goals can lead to aggressive sales tactics. At some point, this can escalate into accounting and disclosure issues.
Under revenue recognition principles, a sale should not be recognized until the risks and rewards of ownership have been passed to the customer. Revenue manipulation often occurs when companies structure or record transactions as completed sales despite retaining significant economic risk.
In the pharmaceutical industry, shipments to wholesalers and distributors may appear to be completed sales on the surface. In reality, expanded return rights, extended payment terms and special fees or discounts can significantly reduce risk transfer to the customer.
While companies believe internal controls will surface warning signs, internal control environments previously considered effective often don’t prevent or detect such issues. In particular, when special sales terms aren’t communicated to the accounting and compliance functions, manipulation can remain hidden – sometimes for months or even years.
Common Patterns of Revenue Manipulation
Over the course of many FTI Consulting engagements, several recurring themes emerge in pharmaceutical industry revenue manipulation. Examples include:
Accelerating Revenue Recognition (Channel Stuffing)
Channel stuffing is a deceptive business practice in which a company forces more products through its distribution chain than retailers or distributors can realistically sell. In one instance, whistleblower allegations led to an internal investigation that uncovered aggressive sales terms offered to meet earnings expectations.
Because the modified terms significantly limited the customer’s inventory risk, the investigation concluded that the company had materially misstated revenue related to not only the timing of the initial revenue recognition but also due to the judgments and estimates related to Gross-to-Net reserves.
Accelerating Scheduled Orders (Revenue Pull-Forwards)
Another whistleblower alleged that a company pressured wholesale customers to accept more inventory at quarter-end than the amount justified by underlying demand, effectively pulling forward revenue by artificially accelerating orders. An internal investigation identified a recurring pattern of quarter-end sales spikes that helped the company meet its earnings targets.
The findings also revealed that customers received waivers allowing them to hold excess inventory above contractual days-on-hand limits. However, while the practice distorted sales trends and misled investors, it did not materially change the transfer of risk and therefore did not violate revenue recognition rules.
Why Pharmaceutical Revenue Recognition Is Particularly Vulnerable
Determining net revenue for pharmaceutical companies is complex and highly influenced by rebates, chargebacks, returns and other forms of variable consideration. While a pharmaceutical company typically sells at the wholesale acquisition cost, the net revenue it realizes is often lower and subject to many management estimates.
This gap between gross and net revenue further complicates revenue recognition. While creative accounting may technically comply with accounting rules, it can mask or disguise conduct intended to manipulate financial results.
In particular, new pharmaceutical product launches make net revenue inherently difficult to predict. Absent historical experience with key assumptions such as inventory returns and customer mix, management must make subjective assumptions.
To ensure that Gross-to-Net reserves are defensible, stress testing of baseline assumptions is critical. Furthermore, choosing relevant analogs and analyzing underlying demand statistics (such as “EDI 867” data) is essential.
How to Choose the Right Investigators for Suspected Revenue Manipulation
Because pharmaceutical revenue manipulation often hides within ordinary business activity, companies evaluating investigation providers should ask:
- Does the team possess both technical accounting and forensic investigative expertise?
- Do they have significant experience with pharmaceutical industry revenue recognition in general, and with channel stuffing and pull-forwards schemes in particular?
- Do they understand how best to address the expectations of the auditors and the SEC?
- Can they translate complex findings into clear conclusions for auditors, boards, management teams and the SEC?
Revenue manipulation thrives within complex value chains. The pharmaceutical industry’s extensive distribution networks, complicated pricing, and modified sales terms can obscure underlying economics and delay identifying potential issues. The most effective response involves not only identifying accounting and disclosure issues, but also understanding how they occurred, strengthening governance and addressing the gaps that allowed them to happen. Organizations that do so are better positioned to mitigate regulatory scrutiny, protect stakeholder trust and prevent future recurrence.
The views expressed herein are those of the author(s) and not necessarily the views of FTI Consulting, Inc., its management, its subsidiaries, its affiliates, or its other professionals.
Related Insights
Related Information
Published
October 12, 2026
Key Contacts